Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human TAK-102 in GPC3-expressing solid tumors
jRCT1080225204Phase 1Completed
- Sponsor
- Takeda
- Start
- May 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAK-102 in Nonhematologic neoplasms (3 cohorts), sponsored by Takeda. Primary endpoint: Safety and tolerability of TAK-102 (dose-limiting toxicities, ICANS, CRS, adverse events). Started May 2020; status: completed.
02
Drugs
TAK-102
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT1080225204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080225204.